Everolimus-eluting stents safe, effective in complex patients at 1 year

In patients with small-vessel coronary artery disease, stenting creates a special set of concerns for providers. A study with XIENCE V everolimus-eluting stents has demonstrated that they are safe and effective in patients with small-vessel disease at one-year follow-up.

Published July 1 in Catheterization and Cardiovascular Interventions, researchers explored the use of XIENCE V everolimus-eluting stents (Abbott Vascular) in both a small- and a nonsmall-vessel cohort of patients.

While the small-vessel cohort had more complex lesions, the research team led by James B. Hermiller, MD, of St. Vincent Heart Center of Indiana in Indianapolis, found that the one-year clinical outcomes between the small-vessel and nonsmall-vessel cohorts were similar.

In the first 30 days, fewer members of the small-vessel cohort experienced definite or probable stent thrombosis, although over the longer term, both cohorts were comparable, at 0.37 percent vs. 0.4 percent. At one-year follow-up, the rate of academic research consortium defined MI and cardiac death was 4.5 percent in the small-vessel group and 5.1 percent in the nonsmall-vessel group. The target lesion revascularization rate was 3.8 percent in the small-vessel group vs. 3 percent in the nonsmall-vessel group.

Only major bleeding differed between the two groups: Rates were 1.4 percent for the small-vessel group while they were 2.6 percent in the nonsmall-vessel group.

The study was designed to reflect complex, real-world patients. Hermiller et al enrolled approximately 2,000 patients, with 838 in the small-vessel cohort. The findings at one year are consistent with prior studies on XIENCE V everolimus-eluting stents in low-risk patients, which demonstrated the safety and efficacy of the device.

This trial was sponsored by Abbott Vascular.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.